Combined immunological agent and sensitizing agent for the treatment of cancer

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes a cancer treatment method and kit that combines an immunological agent (such as an antibody or antibody-drug conjugate that targets specific antigens on cancer cells, inducing apoptosis) with a sensitizing agent (such as cyclosporin A or valproic acid and their analogs). The combination therapy produces a stronger, synergistic anti-cancer effect compared to either the immunologic agent or the sensitizer alone, allowing for enhanced inhibition of cancer cell proliferation.

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment of various cancers including leukemias (such as B-cell leukemia), lymphomas, melanomas, and solid tumors expressing specific antigens targeted by the immunologic agent.
• Personalized cancer therapies where a patient’s cancer expresses defined surface antigens.
• Adjunct therapy to improve the effectiveness of existing antibody-based cancer drugs by adding sensitizing agents.
• Development of pharmaceutical kits for oncologists to use in hospital or outpatient settings.

BenefitsContent extracted from patent full text and abstract with AI.

• Synergistic anti-cancer effect (greater efficacy than monotherapy, enabling more cancer cell death).
• Potential to lower the required dose of toxic immunological agents, reducing side effects.
• Versatility in application to a variety of cancers, provided the cancer cells express appropriate surface antigens.
• Improved outcomes for patients through enhanced inhibition of tumor growth and proliferation.
• Flexibility in treatment scheduling (sensitizer can be given before, during, or after immunologic agent).
• Potential to overcome or delay the development of drug resistance in cancer cells.
• Supports the development of standardized combination therapy kits for clinical use.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

A method and kit for inhibiting the proliferation of cancer cells are disclosed, based on a combination of an apoptosis-inducing immunologic agent, and a sensitizing agent. When used in cancer therapy, the two agents in combination enhance the anti-cancer treatment efficacy obtained with the immunologic agent or the sensitizing agent alone, by a supraadditive amount.